Ulcerative Colitis Market Analysis, Trends, Size, Share, Growth & Forecast 2018 - 2026

                                                                            
The mucosal lining of the colon is affected by ulcerative colitis, a chronic idiopathic inflammatory bowel disease (IBD) affecting the gastrointestinal system.

             Ulcerative Colitis Market


The mucosal lining of the colon is affected by ulcerative colitis, a chronic idiopathic inflammatory bowel disease (IBD) affecting the gastrointestinal system. It is most common in people between the ages of 15 and 30. Along with Crohn's disease, ulcerative colitis is one of the two main kinds of IBD. Unlike Crohn's disease, which can affect any region of the digestive tract, ulcerative colitis usually affects just the large intestine. The exact aetiology of the sickness has yet to be discovered. According to the existing evidence, it could be the outcome of an overreactive immune response to normal bacteria and other chemicals in the gastrointestinal system. Due to inflammation and the formation of open sores (ulcers) in the large intestine (colon) and rectum, ulcerative colitis causes abdominal pain and bloody diarrhoea.

The rising prevalence of ulcerative colitis disease, which affects millions of individuals worldwide, is driving the expansion of the global Ulcerative Colitis Market. Furthermore, significant R&D and investment by key players in the development of innovative medicines for UC therapy, as well as an increase in government and non-government organisations funding biologics research, are fueling market expansion. However, the market is restrained by the expiration of drug patents and strict government restrictions governing biosimilar approval. Unmet needs in the treatment of UC present significant prospects for market expansion.

Market Segmentation:

Global Market by Drug Type

  • Infliximab
  • Golimumab
  • Adalimumab
  • Vedolizumab
  • Mesalamine
  • Budesonide
  • Balsazide

Global Market by Dosage Form
  • Parenteral
  • Oral

Global Market by Geography
  • North America
  • Europe
  • APAC
  • Latin America
  • Middle East
  • Africa
The market is growing because to the rising prevalence of ulcerative colitis around the world. The industry is also benefiting from increased spending on research and development capabilities to create innovative treatments. The expansion of the ulcerative colitis therapy industry is also being fueled by increased efforts by governmental and non-governmental organisations to do biologics research.

Some major companies playing leading role in ulcerative colitis market are AbbVie Inc., Hospira, Celltrion Healthcare, Johnson and Johnson, F. Hoffmann-La Roche AG, Warner Chilcott, Janssen Pharmaceuticals Inc. and Takeda Pharmaceuticals Company Ltd.

Comments

Popular posts from this blog

Molecular Sieves Catalyst Market: Global Company Analysis and Forecast 2018 – 2026 | Albemarle Corporation, W. R. Grace and Company, Silkem Ltd., Sinopec Group, and JGC Catalysts & Chemicals Ltd.

Biolubricants Market Size, Share, Growth, Opportunities, Global Analysis and Opportunity Assessment 2019 – 2027

Shared Services Market by Function, By Number of Services and By Region – Global Opportunities & Forecast 2019 - 2027